FairValueLabs Valuation System Value Investment
PATH

UiPath, Inc. (PATH) Stock Analysis — Fair Value, Risk & Moat Rating

NYQ · Technology · Software - Infrastructure

$10.89 Overvalued 0.11 (1.0%) As of Apr 22, 2026 Not a buy/sell recommendation. See disclaimer.
Overall Verdict Caution
3.51
Altman Z-ScoreSafe Zone
$9.26
Fair ValueOvervalued (-17.6%)
2.6
Moat RatingNarrow moat · eroding
TL;DR · Audit Summary

Is UiPath, Inc. a safe investment right now?

UiPath, Inc.'s Altman Z-Score of 3.51 places it in the safe zone. Our fair value estimate is $9.26 (Overvalued). Moat rating: 2.6/5 stars.

Price Chart · PATH
Section 01 · Financial Health

Could UiPath, Inc. go bankrupt? Altman Z-Score analysis

3.51

Z-Score of 3.51 is above 3.0, indicating the company is financially healthy by this metric.

  • Below 1.8 — Distress Zone (high bankruptcy risk)
  • 1.8 to 3.0 — Gray Zone (elevated uncertainty)
  • Above 3.0 — Safe Zone (financially healthy)

What drives PATH's Z-Score?

Altman Z-Score components for PATH
ComponentFormulaValueWeightContribution
A · Working Capital / Total AssetsWC / TA0.4211.20.51
B · Retained Earnings / Total AssetsRE / TA-0.53651.4-0.75
C · EBIT / Total AssetsEBIT / TA0.01793.30.06
D · Market Cap / Total LiabilitiesMCap / TL5.31040.63.19
E · Revenue / Total AssetsRev / TA0.50661.00.51

How has PATH's financial health changed over time?

3.0 Safe1.8 Distress0.01.22.33.54.72023202420252026
PATH Z-Score history
YearZ-ScoreZone
20234.07Safe
20243.83Safe
20253.41Safe
20263.51Safe

Source: Calculated from PATH's latest 10-K filing on SEC EDGAR.

Section 02 · Fair Value Estimate

What is UiPath, Inc. actually worth?

FVL Fair Value$9.26
vs
Market Price$10.89
Overvalued -17.6% Stock trades 17.6% above our estimated fair value of $9.26.

How we calculated this

FVL Valuation Model
InputValueSource
Predicted EPS (α)$0.52Proprietary blend of reported actuals (4Q actual) + analyst consensus, weighted by α
Last Year EPS$-0.13Annual report (SEC EDGAR)
Analyst Consensus EPS (This Year)$0.8016 analysts consensus
Trailing P/E20.9xCurrent market pricing
Fair P/E (β discount)17.8xTrailing PE adjusted by value discount factor β, hard-capped
Earnings Trend (γ)StableDirectional signal: predicted vs trailing EPS

Wall Street Reference: Analyst consensus target price is $13.80 (16 analysts). This is shown for reference only and is not used in our valuation model.

Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.

Section 03 · Competitive Moat

Does UiPath, Inc. have a durable competitive advantage?

★★½☆☆
Narrow moat · eroding

Moat rating: 2.6/5.

What makes up PATH's moat score?

ROIC Stability

★★☆☆☆

ROIC variability over the past decade. Score: 2/5.

Gross Margin Trend

★★★☆☆

Gross margin trajectory over the past decade. Score: 3/5.

Switching Costs

★★★☆☆

Estimated customer lock-in based on margin level. Score: 3/5.

How stable is PATH's return on invested capital?

0%-23%-15%-7%2%10%2023202420252026
PATH ROIC history
YearROICTrend
2023-18.1%
2024-8.2%Rising
2025-8.8%Stable
20262.7%Rising

Source: ROIC calculated from SEC EDGAR filings.

Section 04 · Dividend Safety

Is UiPath, Inc.'s dividend safe?

Status Suspended UiPath, Inc. has suspended its dividend. No payout is currently being made to shareholders.
Section 05 · Financial Summary

UiPath, Inc.'s key financial metrics

PATH financial summary
MetricLatest1Y Ago3Y AgoTrend
Revenue $1.6B $1.4B $1.1B Rising
Net Income $0.3B −$0.1B −$0.3B Rising
Free Cash Flow $0.4B $0.3B −$0.0B Rising
Gross Margin 83.2% 82.7% 83.0% Stable
Section 06 · Lab Signals

Recent events that affect our PATH analysis

EARNINGS

PATH earnings report scheduled

Lab Impact

Upcoming report. Consensus EPS estimate: $0.16. Revenue estimate: $397.5M. Our current Fair Value: $9.26 — a significant beat or miss could shift this estimate.

ANALYST

PATH analyst consensus: 16% bullish (3 of 19 analysts)

Lab Impact

1 Strong Buy, 2 Buy, 15 Hold, 0 Sell, 1 Strong Sell. Consensus target: $13.80 (26.7% upside). Compare with our independent Fair Value: $9.26.

FILING

PATH filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

FILING

PATH filed annual report (10-K)

Lab Impact

Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →

EARNINGS

PATH beat EPS estimates by 18.1%

Lab Impact

Reported EPS: $0.30 vs estimate $0.25. Earnings strength supports our Fair Value of $9.26 (15.0% below current price).

FILING

PATH filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

FILING

PATH filed quarterly report (10-Q)

Lab Impact

Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →

EARNINGS

PATH beat EPS estimates by 1759.9%

Lab Impact

Reported EPS: $0.37 vs estimate $-0.02. Earnings strength supports our Fair Value of $9.26 (15.0% below current price).

FILING

PATH filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

FILING

PATH filed quarterly report (10-Q)

Lab Impact

Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →

EARNINGS

PATH beat EPS estimates by 79.8%

Lab Impact

Reported EPS: $0.15 vs estimate $0.08. Earnings strength supports our Fair Value of $9.26 (15.0% below current price).

FILING

PATH filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

FILING

PATH filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

FILING

PATH filed quarterly report (10-Q)

Lab Impact

Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →

EARNINGS

PATH beat EPS estimates by 7.2%

Lab Impact

Reported EPS: $0.11 vs estimate $0.10. Earnings strength supports our Fair Value of $9.26 (15.0% below current price).

FILING

PATH filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

FILING

PATH filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

FILING

PATH filed annual report (10-K)

Lab Impact

Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →

EARNINGS

PATH beat EPS estimates by 34.0%

Lab Impact

Reported EPS: $0.26 vs estimate $0.19. Earnings strength supports our Fair Value of $9.26 (15.0% below current price).

FILING

PATH filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

Section 07 · FAQ

Common questions about UiPath, Inc.

What is UiPath, Inc. stock price today?

UiPath, Inc. (PATH) stock price is $10.89 as of the latest market close, traded on the NYSE exchange.

What does UiPath, Inc. do?

UiPath, Inc. provides an automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. It offers the UiPath platform, an integrated enterprise software platform that enables AI agents, robots, people, and models to work together in coordinated workflows.

What is UiPath, Inc. market cap?

UiPath, Inc. has a market capitalization of $5.82B, classifying it as a mid-cap stock in the Technology sector.

What sector and industry is PATH in?

UiPath, Inc. operates in the Technology sector, specifically within the Software - Infrastructure industry. It trades on the NYSE under the ticker symbol PATH.

Is PATH stock overvalued or undervalued?

Based on our valuation model, UiPath, Inc. trades 17.6% above our fair value estimate — potentially overvalued.

  • FairValueLabs Fair Value: $9.26
  • Current Price: $10.89
  • Valuation Zone: Overvalued
What is PATH stock forecast and analyst target price?

Based on 16 Wall Street analysts, the consensus price target for UiPath, Inc. is $13.80, implying upside of 26.7% from the current price.

  • Analyst High Target: $17.00
  • Analyst Low Target: $12.00

Note: Analyst targets are shown for reference and are not used in our valuation model.

Is UiPath, Inc. revenue and earnings growing?

Here are the analyst consensus growth estimates for UiPath, Inc.:

  • Revenue growth (current year est.): 9.1%
  • EPS growth (current year est.): 11.1%
  • Revenue growth (next year est.): 8.4%
  • EPS growth (next year est.): 12.1%
What are UiPath, Inc.'s key financial metrics?
MetricLatestTrend
Revenue$1.6BRising
Net Income$0.3BRising
Free Cash Flow$0.4BRising
Gross Margin83.2%Stable
What is PATH's P/E ratio?

The price-to-earnings ratio measures how much investors pay per dollar of earnings:

  • Trailing P/E (last 12 months): 20.9x
  • Forward P/E (next 12 months est.): 12.2x
  • FairValueLabs Fair P/E: 17.8x
How volatile is PATH stock?

UiPath, Inc. has a beta of 1.02, meaning it is roughly in line with overall market volatility. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.

How much cash and debt does UiPath, Inc. have?

UiPath, Inc.'s balance sheet shows:

  • Total Cash: $1.47B
  • Total Debt: $81.2M
  • Net Cash Position: $1.39B

A positive net cash position means the company holds more cash than debt, reducing financial risk.

What is UiPath, Inc.'s free cash flow?

UiPath, Inc. generated $473.6M in trailing twelve-month free cash flow (from $371.2M in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.

Does UiPath, Inc. pay a dividend?

UiPath, Inc. does not currently pay a regular dividend to shareholders. The company may be reinvesting all profits back into growth, or it may have suspended its dividend.

Is UiPath, Inc. at risk of going bankrupt?

UiPath, Inc.'s Altman Z-Score is 3.51, placing it in the safe zone (above 3.0) — bankruptcy risk is low. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.

Does UiPath, Inc. have a durable competitive advantage?

UiPath, Inc. scores 2.6/5 stars (Narrow moat · eroding) in our moat analysis:

  • ROIC Stability: 2/5
  • Gross Margin Trend: 3/5
  • Switching Costs: 3/5

A score above 3.5 suggests meaningful pricing power and a defensible market position.

What is PATH's return on equity (ROE)?

UiPath, Inc.'s return on equity is 14.4%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.

How do I buy PATH stock?

PATH shares can be purchased through any brokerage account that provides access to the NYSE. Common steps:

  1. Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
  2. Search for ticker symbol PATH
  3. Place a market or limit order for your desired number of shares

This is not investment advice. Always do your own research before buying any stock.

Is PATH a value stock or speculative?

FairValueLabs classifies UiPath, Inc. as Value Investment. It exhibits consistent profitability, reasonable valuation, and financial stability — characteristics of a traditional value investment.

Who is the CEO of UiPath, Inc.?

The current CEO of UiPath, Inc. is Mr. Daniel Solomon Dines.

What is PATH's earnings per share (EPS)?

Earnings per share measures the company's profit allocated to each outstanding share:

  • Trailing EPS (last 12 months): $0.52
  • Forward EPS (next 12 months est.): $0.90
  • Analyst consensus EPS (this year): $0.80
  • Analyst consensus EPS (next year): $0.90

FairValueLabs Disclaimer

All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.

This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.

Last updated: Apr 22, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.

PATH analysis methodology: How we calculate fair value, Z-Scores, and moat ratings